Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Eli Lilly announced positive Phase 3 clinical trial results for Jaypirca, showing it significantly reduces disease progression in patients with previously treated CLL/SLL. The study is the first to demonstrate superiority over a venetoclax-containing control arm in this patient population.
Why it matters
This represents a major advancement in oncology, offering a new, more effective treatment option for patients with relapsed or refractory blood cancers.
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor, reflects current practice patterns
The article is a standard corporate press release reporting clinical trial data without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in